Total Payments
$189,565
2024 Payments
$12,267
Companies
66
Transactions
2,410
Medicare Patients
6,132
Medicare Billing
$929,447
Payment Breakdown by Category
Other$143,230 (75.6%)
Food & Beverage$38,543 (20.3%)
Travel$5,921 (3.1%)
Consulting$1,463 (0.8%)
Education$348.71 (0.2%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $143,230 | 126 | 75.6% |
| Food and Beverage | $38,543 | 2,236 | 20.3% |
| Travel and Lodging | $5,921 | 17 | 3.1% |
| Consulting Fee | $1,463 | 5 | 0.8% |
| Education | $348.71 | 25 | 0.2% |
| Gift | $59.40 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $73,732 | 204 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $35,917 | 206 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $30,982 | 87 | $0 (2021) |
| Lilly USA, LLC | $22,656 | 253 | $0 (2024) |
| Novo Nordisk Inc | $3,712 | 245 | $0 (2024) |
| Amgen Inc. | $2,987 | 189 | $0 (2024) |
| Mannkind Corporation | $2,564 | 204 | $0 (2024) |
| Abbott Laboratories | $2,414 | 159 | $0 (2024) |
| Dexcom, Inc. | $2,119 | 164 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,268 | 59 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,267 | 342 | Boehringer Ingelheim Pharmaceuticals, Inc. ($4,484) |
| 2023 | $17,833 | 431 | Lilly USA, LLC ($6,914) |
| 2022 | $12,529 | 387 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,979) |
| 2021 | $16,778 | 242 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,787) |
| 2020 | $11,948 | 200 | Boehringer Ingelheim Pharmaceuticals, Inc. ($5,944) |
| 2019 | $43,403 | 253 | Boehringer Ingelheim Pharmaceuticals, Inc. ($19,135) |
| 2018 | $39,114 | 234 | Boehringer Ingelheim Pharmaceuticals, Inc. ($20,279) |
| 2017 | $35,692 | 321 | Janssen Pharmaceuticals, Inc ($14,976) |
All Payment Transactions
2,410 individual payment records from CMS Open Payments — Page 1 of 97
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Endocrinology | ||||||
| 12/30/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $9.25 | General |
| Category: Endocrinology | ||||||
| 12/23/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $5.64 | General |
| Category: Endocrinology | ||||||
| 12/19/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/18/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $40.57 | General |
| Category: Endocrinology | ||||||
| 12/18/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: Diabetes Care | ||||||
| 12/17/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $29.91 | General |
| 12/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $7.68 | General |
| Category: LIVER DISEASE | ||||||
| 12/16/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Diabetes | ||||||
| 12/12/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $23.37 | General |
| 12/12/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $5.91 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | Tolmar, Inc. | JATENZO (Drug) | Food and Beverage | Cash or cash equivalent | $13.80 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 12/10/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $40.83 | General |
| Category: LIVER DISEASE | ||||||
| 12/10/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: DIABETES | ||||||
| 12/09/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $19.44 | General |
| Category: Insulin Pump | ||||||
| 12/07/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $8.16 | General |
| Category: LIVER DISEASE | ||||||
| 12/06/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $9.54 | General |
| Category: DIABETES MEDICINE | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $9.64 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $14.62 | General |
| Category: Insulin Pump | ||||||
| 12/03/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 12/02/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Diabetes | ||||||
| 12/02/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $7.07 | General |
| 11/27/2024 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $11.59 | General |
| Category: DIABETES MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,590 | 2,720 | $729,310 | $276,057 |
| 2022 | 12 | 1,563 | 2,563 | $620,755 | $232,178 |
| 2021 | 12 | 1,611 | 2,970 | $617,252 | $238,743 |
| 2020 | 10 | 1,368 | 2,248 | $545,020 | $182,469 |
Total Patients
6,132
Total Services
10,501
Medicare Billing
$929,447
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 824 | 1,855 | $453,070 | $182,805 | 40.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 159 | 159 | $74,745 | $27,901 | 37.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 139 | 139 | $43,920 | $17,935 | 40.8% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 149 | 151 | $50,450 | $14,049 | 27.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 65 | 68 | $36,720 | $9,880 | 26.9% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2023 | 65 | 68 | $23,800 | $7,887 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 82 | 99 | $18,990 | $7,031 | 37.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 79 | $15,405 | $5,237 | 34.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 51 | 80 | $8,070 | $2,214 | 27.4% |
| 10006 | Fine needle aspiration biopsy using ultrasound guidance, each additional growth | Office | 2023 | 21 | 22 | $4,140 | $1,119 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 702 | 1,528 | $371,245 | $149,359 | 40.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 103 | 103 | $47,490 | $17,800 | 37.5% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 151 | 160 | $53,600 | $15,140 | 28.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 98 | 98 | $32,130 | $12,767 | 39.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 57 | 64 | $34,560 | $10,553 | 30.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 57 | 172 | $33,540 | $10,133 | 30.2% |
| 10005 | Fine needle aspiration biopsy using ultrasound guidance, first growth | Office | 2022 | 55 | 63 | $22,050 | $7,504 | 34.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 68 | 78 | $14,340 | $5,677 | 39.6% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 116 | 126 | $4,410 | $1,221 | 27.7% |
| 10006 | Fine needle aspiration biopsy using ultrasound guidance, each additional growth | Office | 2022 | 21 | 23 | $4,305 | $1,146 | 26.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 14 | 15 | $1,755 | $443.74 | 25.3% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 121 | 133 | $1,330 | $435.39 | 32.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 610 | 1,440 | $349,992 | $147,375 | 42.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 141 | 141 | $65,205 | $25,074 | 38.5% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 151 | 164 | $55,560 | $17,279 | 31.1% |
About Dr. Bashar Saad, MD
Dr. Bashar Saad, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in San Dimas, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275611360.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bashar Saad, MD has received a total of $189,565 in payments from pharmaceutical and medical device companies, with $12,267 received in 2024. These payments were reported across 2,410 transactions from 66 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($143,230).
As a Medicare-enrolled provider, Saad has provided services to 6,132 Medicare beneficiaries, totaling 10,501 services with total Medicare billing of $929,447. Data is available for 4 years (2020–2023), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location San Dimas, CA
- Active Since 11/02/2006
- Last Updated 11/12/2024
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1275611360
Products in Payments
- JARDIANCE (Drug) $93,689
- INVOKANA (Drug) $30,836
- SOLIQUA (Drug) $13,358
- TOUJEO (Drug) $9,930
- TOUJEO (Biological) $5,014
- SOLIQUA 100/33 (Drug) $4,111
- SOLIQUA 100/33 (Biological) $3,183
- AFREZZA (Drug) $2,564
- Dexcom G6 Transmitter (Medical Supply) $1,550
- FARXIGA (Drug) $1,081
- Ozempic (Drug) $1,009
- Repatha (Biological) $956.28
- EVENITY (Biological) $861.05
- Rybelsus (Drug) $811.09
- FREESTYLE LIBRE 2 (Device) $799.17
- FREESTYLE LIBRE 3 (Device) $788.99
- BD Nano 2nd Gen Pen Needle (Device) $632.76
- Omnipod (Device) $552.42
- MOUNJARO (Drug) $535.95
- TRULICITY (Drug) $524.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.